• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 10, 2018

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Researchers from Yale University and the Russian Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry have developed an ultra high-throughput (uHT) microfluidic method that allowed them to profile the activity of complex microbiomes, and used it to isolate an antibiotic that was active against Staphylococcus aureus from the saliva of the Siberian bear.  Read More

Regulatory actions for Sept. 7, 2018

Read More

Clinical data for Sept. 7, 2018

Read More

Financings

Novus Therapeutics Inc., of Irvine, Calif., said it elected to postpone its public offering due to market conditions, including valuation sensitivity at the current share price. As of June 30, the company, which develops products for ear, nose and throat disorders, had about $19.2 million in cash and equivalents.  Read More

Other news to note

Supernus Pharmaceuticals Inc., of Rockville, Md., said the U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that Twi Pharmaceuticals Inc., of Taipei City, Taiwan, greater China, infringed three valid Oxtellar XR Orange Book patents.  Read More

Priority pace: Alexion's Soliris wins nod as China speeds up review process

HONG KONG – Alexion Pharmaceuticals Inc.'s blockbuster drug, Soliris (eculizumab), was granted a rapid approval by China's drug regulator, the National Medical Products Administration (NMPA, formerly CFDA), for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Read More

Indian rupee depreciation is a good news, bad news scenario for drugmakers

HONG KONG – Some outward-looking Indian drugmakers may be benefiting from the cheapest rupee ever, but others, which hedged their currency bets, could take a hit. Read More

Zealand trades 'lixi' for liquidity in $205M royalty deal

DUBLIN – Zealand Pharma A/S is walking away from its longstanding alliance with Sanofi SA in type 2 diabetes by selling off future income streams from lixisenatide, the glucagon-like-peptide-1 (GLP-1) agonist it discovered, to Royalty Pharma in a $205 million cash deal. Royalty, of New York, will receive sales royalties and potentially $85 million in future milestones from Paris-based Sanofi, although Copenhagen, Denmark-based Zealand will remain eligible for a final payment of up to $15 million, which it expects to receive in 2020. The trigger for that payment has not been disclosed. Read More

Pfizer catalyzer? Pharma VC board seat more good than bad, 'firsthand look'

BOSTON – During a panel talk at Biopharm America on how collaborations between pharmaceutical firms and venture capital (VC) are changing the industry, New York-based Pfizer Inc.'s Anthony Berry said that "oftentimes we might look to join [as a limited partner (LP)] in a fund that might have a specific niche or opportunity" representing "a complement to what we're doing, not necessarily in direct competition with something we might be doing on our own." Such moves "certainly help us get a firsthand look at those companies from a different perspective than just being shopped around from the outside." Read More

Hansoh joins growing HKEX IPO queue, undeterred by volatility; China to follow?

HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. filed for an IPO in Hong Kong late last week, making it the 11th biopharma company to seek a listing on the Hong Kong Stock Exchange (HKEX) since May and following Ascentage Pharma Group International's IPO a week earlier. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe